Stocktoria
Semnur Pharmaceuticals, Inc. SMNR
OTC · stock · Pharmaceutical Preparations · IPO 2022-04-07
Semnur Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2022 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $2.5M | $1.7M | — | — |
| Operating income | -$160.4M | -$4.7M | -$3.2M | — |
| Interest expense | — | $96,242 | $36,909 | — |
| Income tax | $0 | $0 | — | — |
| Net income | -$160.4M | -$4.7M | $632,536 | -$419,390 |
| EPS (diluted) | $-0.78 | $-0.02 | — | — |
| Operating cash flow | -$5.9M | -$4.9M | -$632,783 | -$426,095 |
| Cash & equivalents | $20,000 | $12,000 | $204,464 | $819,747 |
| Total assets | $1.3M | $6.7M | $50.7M | $86.3M |
| Total liabilities | $22.1M | $49.5M | $8.5M | $4.2M |
| Shareholders' equity | -$20.8M | -$42.8M | -$38.1M | -$3.3M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Net income growth | — | -841.5% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.